Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.

Adult Aged Busulfan / adverse effects Graft vs Host Disease / etiology Hematopoietic Stem Cell Transplantation / adverse effects Humans Middle Aged Primary Myelofibrosis / diagnosis Thiotepa Transplantation Conditioning Vidarabine / analogs & derivatives
HSCT TBF Thiotepa busulfan fludarabine myelofibrosis

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
02 2021
Historique:
pubmed: 6 10 2020
medline: 28 4 2021
entrez: 5 10 2020
Statut: ppublish

Résumé

We assessed the outcomes associated with thiotepa, busulfan and fludarabine (TBF) conditioning regimen in a cohort of 29 consecutive patients allografted for myelofibrosis (MF). The median age was 56 (range 42-70) years. According to the refined Dynamic International Prognostic Scoring System (DIPSS-plus), 15 (52%) patients were classified as high risk. Graft source was peripheral blood stem cells in 27 patients. Donor type was HLA-matched related (

Identifiants

DOI: 10.1080/10428194.2020.1827246 PMID: 33012207
pubmed: 33012207
doi: 10.1080/10428194.2020.1827246
doi:

Substances chimiques

Thiotepa 905Z5W3GKH
Vidarabine FA2DM6879K
Busulfan G1LN9045DK
fludarabine P2K93U8740

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

419-427

Auteurs

Mara Memoli (M)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Department of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico II, Naples, Italy.
ORCID: 0000-0002-1922-6048

Annalisa Paviglianiti (A)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.

Florent Malard (F)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
INSERM, UMRs 938, Paris, France.
Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.

Giorgia Battipaglia (G)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.

Eolia Brissot (E)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
INSERM, UMRs 938, Paris, France.
Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.

Clémence Médiavilla (C)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.

Antonio Bianchessi (A)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Department of Molecular Medicine, University of Pavia, Pavia, Italy.

Anne Banet (A)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.

Zoé Van de Wyngaert (Z)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.

Tounes Ledraa (T)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.

Ramdane Belhocine (R)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.

Simona Sestili (S)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.

Simona Lapusan (S)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.

Pierre Hirsch (P)

INSERM, UMRs 938, Paris, France.
Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.
AP-HP, Service d'Hématologie biologique, Hôpital Saint Antoine, Paris, France.

Fabrizia Favale (F)

INSERM, UMRs 938, Paris, France.
Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.
AP-HP, Service d'Hématologie biologique, Hôpital Saint Antoine, Paris, France.

Agathe Boussaroque (A)

INSERM, UMRs 938, Paris, France.
Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.
AP-HP, Service d'Hématologie biologique, Hôpital Saint Antoine, Paris, France.

Agnès Bonnin (A)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.

Anne Vekhoff (A)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.

Ollivier Legrand (O)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
INSERM, UMRs 938, Paris, France.
Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.

Mohamad Mohty (M)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
INSERM, UMRs 938, Paris, France.
Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.

Rémy Duléry (R)

Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
INSERM, UMRs 938, Paris, France.
Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Thiotepa-busulfan-fludarabine as a...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Thiotepa-busulfan-fludarabine as a...
questionsmedicales.fr › Composés chimiques organiques › Composés du soufre › Acides du soufre › Acides sulfoniques › Acides alcanesulfoniques › Alcanesulfonates › Méthanesulfonates › Busulfan › Thiotepa-busulfan-fludarabine as a...
questionsmedicales.fr › Maladies du système immunitaire › Maladie du greffon contre l'hôte › Thiotepa-busulfan-fludarabine as a...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation cellulaire › Transplantation de cellules souches › Transplantation de cellules souches hématopoïétiques › Thiotepa-busulfan-fludarabine as a...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Thiotepa-busulfan-fludarabine as a...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Thiotepa-busulfan-fludarabine as a...
questionsmedicales.fr › Hémopathies et maladies lymphatiques › Hémopathies › Maladies de la moelle osseuse › Syndromes myéloprolifératifs › Myélofibrose primitive › Thiotepa-busulfan-fludarabine as a...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azirines › Aziridines › 1,1',1''-Phosphoryltriaziridine › Thiotépa › Thiotepa-busulfan-fludarabine as a...
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Immunosuppression thérapeutique › Conditionnement pour greffe › Thiotepa-busulfan-fludarabine as a...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléoside purique › Vidarabine › Thiotepa-busulfan-fludarabine as a...